Mustang Bio, Inc. (MBIO) — Analyst outlook / Analyst consensus target is. Based on 7 analyst ratings, the consensus is bullish — 7 Buy.
Analysts estimate Earnings Per Share (EPS) of $-40.50 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.57 vs est $-40.50 (beat +93.7%). 2025: actual $-0.39 vs est $-17.50 (beat +97.8%). Analyst accuracy: 0%.
MBIO Analyst Ratings
Buy
Based on 7 analysts giving stock ratings to Mustang Bio, Inc. in the past 3 months
EPS Estimates — MBIO
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$2.57
vs Est –$40.50
▲ 1,475.9% off
2025
Actual –$0.39
vs Est –$17.50
▲ 4,387.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — MBIO
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
